Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010

May 19 2010

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 will be presented at the annual meeting of the American Society of Clinical Oncology on June 5-7, 2010 in Chicago, IL. Each of these three cancer therapies targets a novel pathway with potential for broad application to a wide variety of cancer types.

TRC105 is a monoclonal antibody to CD105, also known as endoglin. CD105 is an endothelial cell membrane receptor that is essential for the process of new blood vessel formation called angiogenesis. By inhibiting angiogenesis and attacking established vessels in tumors, TRC105 is expected to have activity against a wide variety of solid cancer types.

TRC102 is a small molecule inhibitor of base excision repair that reverses resistance to commonly used antimetabolite and alkylating agent chemotherapies.  TRC102 is currently being studied as an oral agent in combination with pemetrexed (Alimta®) and as an intravenous agent in combination with temozolomide (Temodar®).  

TRC093 is a humanized monoclonal antibody to cleaved collagen in the extracellular matrix that inhibits angiogenesis, tumor growth, and metastasis.  TRC093 is expected to have activity against multiple solid tumor types and may also be developed for age-related macular degeneration.

The presentation details are as follows:

TRC105 (Abstract #3013) -- Phase 1 study of TRC105 [anti-CD105 (endoglin) antibody] therapy in patients with advanced refractory cancerSaturday, June 5, 2010, 1:00 PM – 4:00 PM, E Hall D2 (Oral Abstract Session)

TRC102 (Abstract #2576) -- Final results from a phase 1 study of oral TRC102 (methoxyamine HCl), an inhibitor of base-excision repair, to potentiate the activity of pemetrexed in patients with refractory cancerMonday, June 7, 2010, 8:00 AM – 12:00 PM, S Hall A2 (General Poster Session)

TRC093 (Abstract # 3038) -- Final results from a phase 1 study of TRC093 (humanized anti-cleaved collagen antibody) in patients with solid cancerMonday, June 7, 2010, 8:00 AM – 12:00 PM, S Hall A2 (General Poster Session)